HD Medical at CES Unveils HealthyU™, the World’s First Intelligent All-in-one Remote Patient Monitor for Telehealth and Wellness
At CES’21, HD Medical Inc. today introduces HealthyU™, an intelligent remote patient monitoring device, in response to the ongoing challenges of remote Telehealth, Cardiac Care, and Wellness during the pandemic and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005444/en/
HealthyU™, the World’s First Intelligent All-in-one Remote Patient Monitor for Telehealth and Wellness. HD Medical Inc.'s HealthyU™ is an at-home monitoring device that addresses the ongoing challenges of remote Telehealth, Cardiac Care, and Wellness during the pandemic and beyond. (Graphic: Business Wire)
HealthyU™ is the first home device to provide:
- 7-lead ECG (without wires)
- Heart Sounds with Murmur Analysis
- Lung Sounds
- Heart Rate
- Pulse Oximetry (SpO2 / blood oxygen saturation)
- Respiratory Rate
- Cuffless Blood Pressure Trend
The Future of Telehealth, Home Monitoring, and Wellness
As the medical community seek new ways to deliver care, HealthyU™ takes multiple complex healthcare devices and turns them into one easy-to-use device for the patient and the provider to connect via a simple HD App and HD Cloud Platform for Intelligent Insights, or also with any video conferencing and screen sharing tool for Remote Consultation.
Providers can listen live to the heart and lung sounds using HD Steth™, HD Medical’s flagship intelligent stethoscope technology, cleared by FDA in July 2020 for Electronic Stethoscope, Phonocardiograph and Electrocardiograph.
Created with and available first to those with cardiac care and monitoring needs, HealthyU™ is available to clinical partners for research and corporate wellness partners seeking employee wellness offerings of this caliber, as well as for Telehealth pilot programs under IRB Protocol in accordance with FDA Regulations. HD Medical will be seeking Emergency Use Authorization from the FDA to make available in the U.S. and enable fully informed at-home doctor-patient visits during the pandemic and beyond.
HD Medical at CES Unveils HealthyU
“I’ve been treating patients remotely for nearly a year now and the pandemic has severely limited my ability to understand my patient’s condition. As we move forward, telehealth represents a paradigm shift in healthcare delivery during the pandemic and beyond. HealthyU will play a critical role and promises to not only save lives but also improve the quality of life for all patients,” said Dr. Nelson B. Schiller, MD, FACC, FRCP, Professor of Medicine & Anesthesia, UCSF.
"HealthyU is one of those rare medical devices that is truly a game changer in patient care. Being so user friendly and clinically sound, this device can be used in many different clinical scenarios and can truly be a lifesaver for multitudes of patients, who have the possibility of obtaining care while at home," said Dr. Shaun Setty, MD of The Larry and Helen Hoag Endowed Chair of Pediatric Cardiovascular Surgery in Los Angeles, CA.
“2020 has put greater emphasis on the need to advance remote patient monitoring technology, which is why we have prioritized bringing integrated sensors and intelligent insights into the home making it easy for patients to use and viable for providers to leverage during care,” said Arvind Thiagarajan, founder and CEO of HD Medical. “HealthyU™ performs wireless ECG outside of the hospital while incorporating auscultation and other important vitals. By simplifying the remote monitoring process, we’ve ensured this technology can be leveraged by anyone that needs it.”
HealthyU is currently intended for investigational use only, not for sale in the United States until after FDA clearance. HD Medical expects that HealthyU will be available for sale in the US by the third quarter of 2021, subject to FDA clearance process, which is being undertaken expeditiously. In the meantime, HealthyU will be available to clinical partners for research and corporate wellness programs, as well as telehealth pilot programs under the IRB protocol in accordance with FDA regulations.
To become a HealthyU™ partner, email email@example.com.
About HD Medical, Inc.
HD Medical, Inc. is a Silicon Valley-based innovator of digital health solutions for AI-enabled detection and management of cardiovascular disease (CVD). HD Steth has been awarded FDA clearance (K201299). The company delivers its intelligent cardiac care solutions and products globally to medical professionals and institutions through channel partners. Visit www.HealthyU.ai and www.hdmedicalgroup.com.
Note to editors: HealthyU, HD Steth, HD App, and HD Cloud Platform are registered trademarks of HD Medical, Inc. All other product, service or organization names remain the property of their respective owners.
HD Medical, Inc.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GPD Companies, Inc. to Acquire Distrupol22.1.2021 16:33:00 EET | Press release
GPD Companies, Inc., an affiliate of One Rock Capital Partners, LLC (“One Rock”), today announced that it has entered into a definitive agreement to acquire Distrupol, a subsidiary of Univar Solutions Inc. (NYSE: UNVR) and a leading European distributor of thermoplastics to the polymer processing industry. Terms of the transaction, which is expected to close in the first half of 2021, were not disclosed. Headquartered in Surrey, England, with broad geographic reach across Europe, Distrupol has provided value-added sales and application development of thermoplastic resins for over 50 years. Through its decades-long relationships with world class supply partners, the company offers a robust array of superior performance products and solutions that meet the needs of diverse end users from leading and emerging industries, such as the consumer, medical, automotive, and electrical sectors, among others. Distrupol caters to over 1,300 customers across 13 countries with a portfolio of over 4,0
Schlumberger Announces Fourth-Quarter and Full-Year 2020 Results22.1.2021 14:50:00 EET | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the fourth-quarter and full-year 2020. Fourth-Quarter Results (Stated in millions, except per share amounts) Three Months Ended Change Dec. 31, 2020 Sept. 30, 2020 Dec. 31, 2019 Sequential Year-on-year Revenue $5,532 $5,258 $8,228 5% -33% Income (loss) before taxes - GAAP basis $471 $(54) $452 n/m 4% Net income (loss) - GAAP basis $374 $(82) $333 n/m 12% Diluted EPS (loss per share) - GAAP basis $0.27 $(0.06) $0.24 n/m 12% Adjusted EBITDA* $1,112 $1,018 $1,648 9% -33% Adjusted EBITDA margin* 20.1% 19.4% 20.0% 73 bps 6 bps Pretax segment operating income* $654 $575 $1,006 14% -35% Pretax segment operating margin* 11.8% 10.9% 12.2% 90 bps -40 bps Net income, excluding charges & credits* $309 $228 $545 35% -43% Diluted EPS, excluding charges & credits* $0.22 $0.16 $0.39 37% -44% Revenue by Geography International $4,343 $4,210 $5,834 3% -26% North America 1,167 1,034 2,339 13% -50% Other 22 14 55 n/m n/m $5,532 $5,258 $8,228 5% -
JEOL: Release of a New Cold Field Emission Cryo-Electron Microscope CRYO ARM™ 300 II (JEM-3300)22.1.2021 09:00:00 EET | Press release
JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new cold field emission cryo-electron microscope (cryo-EM), the CRYO ARM™ 300 II (JEM-3300), to be released in January 2021. This new cryo-EM has been developed based on the concept of "Quick and easy to operate and get high-contrast and high-resolution images". This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005316/en/ Cold Field Emission Cryo-Electron Microscope CRYO ARM(TM) 300 II (JEM-3300) (Photo: Business Wire) Development Background Recent dramatic improvement of resolution in single particle analysis (SPA) using cryo-EM has led to SPA as an essential method for structural analysis of proteins. To address this market, JEOL released the CRYO ARM™ 300 in 2017. Equipped with a cold field emission gun (Cold FEG) for enhanced resolution and a cryo-stage for loading multiple samples, the CRYO ARM™ 300 has continued to achieve best-in-class res
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment22.1.2021 01:12:00 EET | Press release
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is provided as a co-pack with two injectable medicines — ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine — dosed once monthly, as an option to replace the current antiretroviral (ARV) regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior to initiating treatment of Cabenuva, oral dosing of cabotegravir and rilpivirine should be administered for approximately one month to assess the tolerability of each therapy.1 Lynn Baxter, Head of North America, ViiV H
Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)22.1.2021 00:30:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its Biologics License Application (BLA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The BLA submission is based on data from the Phase 2 POD1UM-202 trial evaluating retifanlimab in previously treated patients with locally advanced or metastatic SCAC who have progressed on, or are intolerant of, standard platinum-based chemotherapy. The trial enrolled 94 patients, including several with well-controlled human immunodeficiency virus (HIV) infection. The study, which was recently presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, resulted in an objective response rate (ORR) of 14% for retifanlimab monotherapy as determined by inde
Wistron and Kalray Announce FURIO1200™ Storage Appliance21.1.2021 19:45:00 EET | Press release
Wistron, a leader in ICT (Information and communications technology) products, and Kalray (Paris:ALKAL) (Euronext Growth Paris: ALKAL), a leading provider in new generation of processors specialized in Intelligent Data Processing from Cloud to Edge, announce the availability of FURIO1200™, a 24-Flash-Drive NVMe-oF based storage node appliance, integrating Kalray’s NVMe-oF K200™ smart storage adapter, powered by its MPPA® Coolidge™ intelligent processor, and Wistron LYMMA chassis. FURIO1200™ is a new type of hyper-fast disaggregated storage solution delivering ultra-high throughput and reliability. It is the ideal solution for Cloud Service Providers and Enterprises running applications with intensive AI and Data Analytics workloads as well as to optimize their next generation storage. Data Centers are undergoing a very important revolution due to the explosion of usages, the surge of data to be processed and the exponential growth of the number of machines to be managed to support this
NumAlim Selects Dawex and Orange Business Services for its Data and Services Exchange Platform21.1.2021 19:40:00 EET | Press release
NumAlim announced an agreement with Dawex, the leader in Data Exchange technology, and Orange Business Services, a network-native digital services company, to deploy its agri-food digital exchange platform. By relying on these two leading players, NumAlim chose secure technological solutions guaranteeing the sovereignty of French food data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005722/en/ (Photo: Dawex) As early as Q1 2021, the NumAlim data and services exchange "Hub" will offer 18,000 companies in the food industry the opportunity to valorize, acquire and enrich all types of data: production, consumption, traceability, consumer opinions and research, as well as a wide range of services based on data (trend analysis, reformulation, regulatory watch…). "NumAlim is the answer to the needs for transparency, value creation and trust expressed by the food industry, consumers, and public authorities.” says Jérôme Fr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom